While the mechanism of CRISPR/Cas9 cleavage is understood, the large variation in mutant recovery for a given target sequence between cell lines is much less clear. We hypothesized that this variation may be due to differences in how the DNA damage response 
INTRODUCTION
Genome engineering is a powerful tool, not only for modifying cells for therapeutic uses, but also for examining endogenous expression and localization of proteins, as well as aiding in deciphering their interactions with other proteins. In terms of semi-targeted insertion into the genome, the phage integrases, particularly phiC31, have been very useful for expressing exogenous cassettes in a variety of plants and animals for both translational and basic science purposes (reviewed in 1-2). However, targeting specific, single loci in the genome relies on homologous recombination (HR), which although highly efficient in yeast and some other simple model organisms (3-5), has been much less efficient in metazoans.
With the development of the zinc-finger nucleases (ZFN; 6) and the TALEnucleases (TALENs; 7), gene editing in metazoans and cells derived from them became a more feasible method of investigation and therapeutic development. These advances in the genome engineering toolbox built on seminal work with the I-SceI endonuclease (8) , and greatly increased the efficiency of HR by introduction of a targeted double-strand break (DSB) in genomic DNA, while also allowing mutagenesis through the error-prone repair pathway due to the overhang-style of break induced by these nucleases.
Whereas the ZFNs and TALENs offered an unprecedented degree of control over where to induce a DSB due their modular, programmable nature, the design and cloning of these tools is challenging. This impediment has been reduced by discovery and application of the CRISPR/Cas9 system, which has proven to be a versatile tool for genome and transcriptome engineering.
Consisting of a nuclease directed to a genomic target by a guide RNA, the engineered version of Cas9 requires only cloning the
20-base targeting sequence for the variant derived from
Streptococcus pyogenes, for example (9) (10) (11) . The major constraint on use of Cas9 is the requirement of a protospacer adjacent motif (PAM) downstream of the target sequence. This site varies in size and sequence between the different Cas9 proteins. For SpCas9, the PAM is canonically NGG (9) , and the protein makes a predominantly blunt-ended DSB three to four bases 5' from the PAM (12, 13) .
Whichever nuclease is used for genome engineering, there are still challenges faced in the efficient generation of the desired clones or organisms. For example, in addition to a rather cryptic target programming system, the ZFNs are highly cytotoxic (14) .
This cytotoxicity is greatly reduced when using TALENs, increasing the efficiency with which the desired modifications can be obtained (14) . The cytotoxicity of the CRISPR/Cas9 varies between different cell lines, but is, unfortunately, high in induced pluripotent and embryonic stem cells (15, 16) , among the prime candidates for targeting. Also, the frequency of off-target mutations appears to be more severe with Cas9, as a recent report found larger deletions around the DSB and more complex rearrangements than previously identified (17) . However, other studies, including both wild-type and nuclease-dead Cas9, have reported extremely high specificity, a virtual lack of true off-target activity, and an absence of complex rearrangements (18) (19) (20) .
Further compounding these issues is the high variance in gene editing efficiency between cell types and lines for a given guide RNA (13, 21) .
We asked if this high variance in gene editing efficiency could be explained by cell-line-specific cell cycle delay or arrest in response to CRISPR/Cas9 treatment. We reasoned that, because Cas9 predominantly generates blunt-ended DSBs (12, 13) , the DNA repair machinery would precisely repair the break through canonical NHEJ, which would enable Cas9 to target and cleave the same sequence again, enabling a cycle of damage and repair. This cycle would be expected to at least delay cells from progressing through the cell cycle and possibly arrest cells (22) . Consequentially, this delay would reduce the efficiency of CRISPR/Cas9-based genome editing by reducing the frequency of modified cells, and the beneficial effect of removal of Cas9 from its target sequence via destabilization of Cas9 itself would be due to reducing this cell cycle delay. Such a destabilized Cas9 has been previously generated by fusing FKBP12-L106P destabilization domain (23) fused to the N-terminus of wildtype Cas9 to generate DD-Cas9 (13, 24) . DD-Cas9 can be inducibly and reversibly stabilized by the addition of the small molecule Shield-1 (13, 23, 24) .
Here, we characterize the response of several human cell lines to wild-type, destabilization domain-linked, and nuclease-dead SpCas9 targeted to the safe harbour locus H11 on chromosome 22 (25). We identify a strong cell cycle delay/arrest phenotype that appears to be dependent on the TP53 status of each cell line. We determine that inhibition and transcript silencing of TP53 reduces the effect of this delay and illustrate that Cas9 appears to block the repair machinery from recognizing the DSB. Furthermore, we show that CRISPR/Cas9 treatment arrests cells to a higher degree than TALEN treatment. (Li-Cor Biosciences) followed by washing 3 times for 5 minutes each with TBST. Membranes were then imaged on a LI-COR Odyssey (LI-COR Biosciences).
MATERIALS AND METHODS

Cell Culture
Cell Cycle Progression Analysis
RPE1 cells were plated one day prior to transfection on poly-L-lysinecoated glass coverslips at 2.5 x 10 4 cells per well in a 24-well plate.
The following day cells were transfected via polyethylenimine with 500 ng of either pKER-Clover/pKER-NLS-Clover or a vector encoding the H11-r1-2 or H11 r2-3 sgRNA and WT-Cas9, DD-Cas9, Cas9-DD, or APEX2-X-dCas9, or a vector encoding wild-type SpCas9-P2A-mClover3, in the presence or absence of 0.5 μM IncuCyte's analysis software was then used to calculate the number of transfected cells per image. Afterwards, the ratio of surviving Clover+ cells in each ara-C replicate relative to the water control for that condition was calculated and compared to a theoretical ratio of 1 using a one-sample t-test.
Statistics
All statistical analysis was carried out using Graphpad Prism 7 for Windows (Graphpad Software, Inc.).
RESULTS
Wild-Type SpCas9 Leads to Dilution of Transfected Cells in the Population by Limiting S-Phase Progression in RPE-1 Cells
Having previously characterized the behaviour of destabilized variants of SpCas9 in HEK293T cells (13) 
Mediators of CRISPR/Cas9-Associated Cell Cycle Arrest
Our comparison of cell cycle progression in different cell lines suggested that TP53 status may mediate cell cycle arrest in response to CRISPR/Cas9 treatment, similar to the conclusion reached by other groups (16, 26) . We then investigated the effect of abrogating TP53 functionality in wild-type RPE-1 cells.
We took a two-prolonged approach of transcript knockdown via the addition of a short-hairpin cassette against TP53 to our WTCas9 vector targeting the H11 locus ( Figure 2A ) and functional protein inhibition via the small molecule pifithrin-α (27, Figure   2B ). We considered additional factors affecting cell cycle 
CRISPR/Cas9-Associated Cell Cycle Arrest is Dependent on Targeting, Cleavage, and the Presence of a Guide RNA
Having investigated the possibility of alleviating CRISPR/Cas9-associated cell cycle arrest, we next sought to identify the molecular mechanism of the arrest. To this end, we reasoned that there are two non-exclusive mechanisms of action: (1) cleavage by Cas9, and (2) targeting and binding DNA by Cas9.
We investigated these possibilities using the EdU-based flow cytometry assay with transfected cells. However, it is unclear if the latter specifically contributes to CRISPR/Cas9-associated cell cycle arrest.
Bound CRISPR/Cas9 Complex Blocks DSB Recognition
Having identified that CRISPR/Cas9-associated cell cycle arrest is To these ends, we adopted a similar experimental design as for the flow-cytometry-based assays, but we used immunofluorescence-based microscopy to assay cells at the end point of 3 days post-transfection ( Figure 4A ). Additionally, we used DD-Cas9 (13) as a way to theoretically remove Cas9 from the DNA and expose the DSB. We modified the DD-Cas9
vector by inserting a self-contained nuclear-localized Clover expression cassette.
To examine whether the cell is capable of recognizing and 
CRISPR/Cas9 Treatment Arrests Cells to a Greater Extent Than
TALEN Treatment
Having identified a cell cycle progression defect in CRISPR/Cas9-treated cells through lack of EdU incorporation, we chose to further investigate if this was truly an arrest phenotype. At the same time,
we wanted to determine if this cell cycle progression defect is unique to the CRISPR/Cas9 system. To this end, we modified vectors encoding a pair of TALENs targeted against the human H11 locus (25) with a self-contained nuclear-localized mClover3 expression cassette ( Figure 5A ).
For the experimental design, we transfected wild-type and TP53 
DISCUSSION
In this work, we find that CRISPR/Cas9 treatment leads to extended cell cycle arrest in some human cell lines. This arrest requires, in part, functional TP53 and RB1, and can be alleviated to a degree by manipulation of TP53 activity. Additionally, we found that this arrest is mediated by DNA cleavage, DNA binding, and the Cas9 protein itself, in descending order of importance.
Furthermore, we provide evidence that the propensity of Cas9 to remain bound to DNA after cleavage reduces the ability of cells to recognize and repair the doublestrand break, and that this too is dependent on functional TP53. 
